ViiV hopes to launch Celsentri in India this year
This article was originally published in Scrip
Executive Summary
ViiV Healthcare, the new holder of rights to Celsentri (maraviroc), hopes to introduce the product in India this year, although it has yet to receive marketing authorisation for the HIV entry inhibitor under its own name in the country.